TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07002216: BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma

Sponsor: University of Miami · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 48 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07002216 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07002216 Rescue Dossier →